Researchers at Duke University have developed an antibody that combats cancer cells while preserving healthy cells. The treatment may provide an alternative option to current immunotherapies that have nasty side effects, the researchers claim.
The paper, published in the journal Cell Reports, is the most recent in a string of studies conducted by the researchers. Previous studies suggested that the antibody could help stymie the advancement of early stage lung cancer. In additional studies, the team found a human derived antibody called complement factor H (CFH) destroyed cancer cells when limited to a specific target.
